No­var­tis’ Plu­vic­to sup­ply ‘ful­ly un­con­strained,’ eyes man­u­fac­tur­ing ex­pan­sion

No­var­tis says that ac­cess to Plu­vic­to is now “ful­ly un­con­strained” as the phar­ma gi­ant plans for man­u­fac­tur­ing ex­pan­sions to en­sure a steady sup­ply of the prostate can­cer ra­dio­ther­a­py.

The com­pa­ny can sup­ply Plu­vic­to to pa­tients with­in two weeks of or­der­ing, said Jee­van Virk, No­var­tis’ head of ra­di­oli­gand ther­a­py ther­a­peu­tic area strat­e­gy. And for next year, it pre­dicts a “com­bined an­nu­al ca­pac­i­ty tar­get of at least 250,000 ra­di­oli­gand ther­a­py dos­es” across its fa­cil­i­ties, Virk told End­points News in an email.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.